Investing

Rhythm Pharmaceuticals : RYTM

RYTM

Stock Data

$117.60

$4.76 (4.21%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for rare neuroendocrine diseases. Its flagship product, IMCIVREE (setmelanotide), targets obesity caused by genetic deficiencies and is in advanced clinical trials. The company, founded in 2008 and based in Boston, Massachusetts, collaborates with several global partners to advance its research and bring new therapies to patients with unmet medical needs. Originally known as Rhythm Metabolic, Inc., it rebranded to its current name in 2015.

Latest Activity

RYTMRhythm Pharmaceuticals

Q2 2026

Aug 4, 7:49am ET

EPS

-$0.73

est -$0.83+12.4%

Revenue

$71M

est $68M+5.3%

IMCIVREE's launch in acquired hypothalamic obesity is scaling faster than modeled, pushing U.S. product revenue to $51 million and beating estimates. Japan launch pending by year-end, European rollouts in 2027.

Loading…

ShareRead more

All Rhythm Pharmaceuticals Articles

2 Articles

Lee Jackson | Jul 27, 2026 at 7:46 AM EDT

Here Are Monday’s Top Wall Street Analyst Research Calls: Alphabet, Clean Harbors, Ford, Huntington Bancshares, Rivian, Rocket Lab, Terawulf, Vale, Warner Bros. Discovery, and More

Wall Street analysts are reshuffling their bets ahead of the busiest earnings week of the quarter, and the moves span…

Lee Jackson | Feb 19, 2026 at 8:09 AM EST

Here Are Thursday’s Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More

Pre-Market Stock Futures: Futures are trading lower on Thursday, as Walmart’s forward outlook was disappointing. Risk-on was back on Wednesday,…